

Günter Breithardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1232779/publications.pdf>

Version: 2024-02-01

79
papers

15,019
citations

156536

32
h-index

100535

70
g-index

90
all docs

90
docs citations

90
times ranked

13046
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. <i>European Heart Journal</i> , 2022, 43, 1219-1230.	1.0	84
2	Thyroid Dysfunction under Amiodarone in Patients with and without Congenital Heart Disease: Results of a Nationwide Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2027.	1.0	3
3	Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 80, 283-295.	1.2	34
4	The dawn of radiofrequency catheter ablation for cardiac arrhythmias. <i>Heart Rhythm</i> , 2021, 18, 485-486.	0.3	4
5	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET). <i>Europace</i> , 2021, 23, 1903-1912.	0.7	15
6	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2021, 144, 845-858.	1.6	111
7	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	1.6	0
8	Ludger Seipel: an early comer in clinical electrophysiology at 80 years. <i>Clinical Research in Cardiology</i> , 2020, 109, 527-528.	1.5	0
9	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020, 383, 1305-1316.	13.9	1,071
10	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 145-152.	1.8	75
11	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	0.8	10
12	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.	1.2	6
13	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. <i>Clinical Cardiology</i> , 2018, 41, 39-45.	0.7	11
14	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.	1.6	30
15	NOACs for Stroke Prevention in Atrial Fibrillation With Valve Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1383-1385.	1.2	2
16	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i> <i>Cardiology</i> , 2017, 120, 1837-1840.	0.7	10
17	Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003337.	2.1	213
18	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69

#	ARTICLE	IF	CITATIONS
19	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	1.2	36
20	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	1.0	266
21	Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term. <i>European Heart Journal</i> , 2015, 36, 1794-1797.	1.0	14
22	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. <i>BMC Neurology</i> , 2015, 15, 129.	0.8	22
23	Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias. <i>Europace</i> , 2015, 17, 1300-1308.	0.7	19
24	Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 364-73.	0.7	34
25	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	1.0	154
26	The quality of oral anticoagulation in general practice in patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2014, 25, 247-254.	1.0	30
27	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
28	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	1.2	181
29	Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. <i>American Heart Journal</i> , 2013, 166, 442-448.	1.2	132
30	Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. <i>Europace</i> , 2013, 15, 486-493.	0.7	308
31	Oral anticoagulation use by patients with atrial fibrillation in Germany. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1053-1065.	1.8	122
32	Left Bundle Branch Block, an Old – New Entity. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 107-116.	1.1	43
33	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
34	Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. <i>Thrombosis and Haemostasis</i> , 2011, 105, 1010-1023.	1.8	69
35	MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T <i>Heart Journal</i> , 2009, 30, 2551-2553.	1.0	15
36	The German Competence Network on Atrial Fibrillation (AFNET). <i>Herz</i> , 2008, 33, 548-555.	0.4	12

#	ARTICLE	IF	CITATIONS
37	The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. <i>Europace</i> , 2008, 11, 423-434.	0.7	352
38	Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. <i>Europace</i> , 2007, 9, 1006-1023.	0.7	254
39	Doppler echocardiography and Tissue Doppler Imaging in the healthy rabbit: Differences of cardiac function during awake and anaesthetised examination. <i>International Journal of Cardiology</i> , 2007, 115, 164-170.	0.8	48
40	Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. <i>Clinical Drug Investigation</i> , 2007, 27, 697-705.	1.1	34
41	Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). <i>European Heart Journal</i> , 2007, 28, 2803-2817.	1.0	335
42	Quest for the Best Candidate. <i>Circulation</i> , 2006, 113, 926-928.	1.6	20
43	Atrial fibrillation management: a prospective survey in ESC Member Countries. <i>European Heart Journal</i> , 2005, 26, 2422-2434.	1.0	770
44	Targeted pharmacological reversal of electrical remodeling after cardioversionâ€”Rationale and design of the Flecainide Short-Long (Flec-SL) trial. <i>American Heart Journal</i> , 2005, 150, 899.e1-899.e6.	1.2	31
45	Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. <i>European Heart Journal</i> , 2004, 25, 1385-1394.	1.0	300
46	Prolonged Atrial Action Potential Durations and Polymorphic Atrial Tachyarrhythmias in Patients with Long QT Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 1027-1033.	0.8	119
47	Directct Epicardial Mapping Can Differentiate Hibernating from Scarred Myocardium: A Validation Study with 18F-FDG-PET. <i>Annals of Noninvasive Electrocardiology</i> , 2002, 7, 349-356.	0.5	3
48	A novel long-QT 5 gene mutation in the C-terminus (V109I) is associated with a mild phenotype. <i>Journal of Molecular Medicine</i> , 2001, 79, 504-509.	1.7	29
49	Intracardiac Tuberculoma Causing "Idiopathic" Ventricular Tachycardia in a Patient Without Detectable Heart Disease. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 118-118.	0.8	5
50	Clinical Value of Electrocardiographic Parameters in Genotyped Individuals with Familial Long QT Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 406-415.	0.5	12
51	Prolonged QRS Duration Increases QT Dispersion But Does Not Relate to Arrhythmias in Survivors of Acute Myocardial Infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 789-795.	0.5	12
52	Absence of circulating microemboli in patients with lone atrial fibrillation. <i>Neurological Research</i> , 1999, 21, 566-568.	0.6	11
53	KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. <i>Nature Genetics</i> , 1997, 17, 267-268.	9.4	441
54	The clinical impact of thallium-201 reinjection for the detection of myocardial hibernation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 407-413.	2.2	14

#	ARTICLE	IF	CITATIONS
55	Internal Defibrillation with Smaller Capacitors: A Prospective Randomized Cross-Over Comparison of Defibrillation Efficacy Obtained with 90-?F and 125-?F Capacitors in Humans. Journal of Cardiovascular Electrophysiology, 1995, 6, 333-342.	0.8	16
56	Bipolar Transvenous Defibrillation: Efficacy of Two Different Positions of the Anode. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 1995-2000.	0.5	7
57	Are there gender differences in patients with coronary artery disease presenting with spontaneous sustained ventricular tachycardia and ventricular fibrillation?. Clinical Cardiology, 1995, 18, 161-166.	0.7	7
58	Trans venous-Subcutaneous Defibrillation Leads:... Journal of Cardiovascular Electrophysiology, 1994, 5, 912-918.	0.8	12
59	Recurrence and Late Block of Accessory Pathway Conduction Following Radiofrequency Catheter Ablation. Journal of Cardiovascular Electrophysiology, 1994, 5, 650-658.	0.8	25
60	A Prospective Randomized Cross-Over Comparison of Mono- and Biphasic Defibrillation Using Nonthoracotomy Lead Configurations in Humans. Journal of Cardiovascular Electrophysiology, 1994, 5, 581-590.	0.8	66
61	Management of Patients with Ventricular Tachyarrhythmias: Does an Optimal Therapy Exist?. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 559-570.	0.5	7
62	Radiofrequency Catheter Ablation of Ventricular Tachycardia Following Implantation of an Automatic Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 1684-1692.	0.5	54
63	Signal Averaging in Patients with Coronary Artery Disease:... Journal of Cardiovascular Electrophysiology, 1993, 4, 609-626.	0.8	7
64	Unexpected Emergence of Manifest Preexcitation Following Transcatheter Ablation of Concealed Accessory Pathways. Journal of Cardiovascular Electrophysiology, 1993, 4, 467-472.	0.8	8
65	Nd: YAG Laser-Photocoagulation: Acute Electrophysiological, Hemodynamic, and Morphological Effects in Large Irradiated Areas. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 52-59.	0.5	4
66	Radiofrequency Ablation of Accessory Pathways: Characteristics of Transiently and Permanently Effective Pulses. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1122-1130.	0.5	16
67	Results and Realistic Expectations with Transvenous Lead Systems. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 665-670.	0.5	56
68	Implantation of a Cardioverter/Defibrillator in the Subpectoral Region Combined with a Nonthoracotomy Lead System. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 367-368.	0.5	27
69	Role of Ventricular Tachycardia Surgery and Catheter Ablation As Complements or Alternatives To the Implantable Cardioverter Defibrillator in the 1990s. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 681-689.	0.5	12
70	Coagulation of Ventricular Myocardium Using Radiofrequency Alternating Current: Bio-Physical Aspects and Experimental Findings. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 187-195.	0.5	87
71	High frequency alternating current ablation of an accessory pathway in humans. Journal of the American College of Cardiology, 1987, 10, 576-582.	1.2	257
72	Electrical and Anatomical Mapping of Different Pathologies: Ischemic, Dilated, and Hypertrophic Cardiomyopathies. , 0, , 376-384.		0

#	ARTICLE	IF	CITATIONS
73	Principles of NavX Mapping. , 0, , 71-79.		0
74	Cardiac Anatomy for Interventional Electrophysiology and Mapping. , 0, , 27-36.		0
75	Legal Implications of Defibrillator Guidelines. , 0, , 60-62.		0
76	Construction and Interpretation of Endocardial Maps: From Basic Electrophysiology to 3D Mapping. , 0, , 11-26.		1
77	Molecular Cardiovascular Imaging with SPECT and PET. , 0, , 454-462.		0
78	Role of Body Surface Mapping. , 0, , 485-491.		0
79	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET): Authors' reply. Europace, 0, , .	0.7	0